Skip to main content

Advertisement

SpringerLink
Log in

Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

The aim of this retrospective single-center study was to analyze the clinical characteristics and outcome of non-Hodgkin lymphoma (NHL) patients with central nervous system (CNS) involvement and to identify prognostic factors for survival. We searched our hospital records for NHL patients diagnosed with CNS involvement from 1982 to 2004, and 43 patients were identified. The median age was 63 years (range 23–88) and the median Karnofsky performance status was 55% (range 10–90). Treatment of CNS lymphoma included intrathecal chemotherapy in 33 patients (77%), systemic chemotherapy in 25 (58%), and radiotherapy in 16 (37%). Twenty-six patients showed a CNS response. The median survival after CNS manifestation was 5 months (range 2 days–82.5+months). Nine patients achieved long-term survival. Low lactate dehydrogenase (LDH) at CNS manifestation and a CNS response to therapy were favorable independent prognostic factors for survival in multivariate analysis (p=0.051 and p<0.0005, respectively), whereas a young age at initial diagnosis, initial CNS involvement, an initially normal LDH, and high-dose chemotherapy for CNS involvement were significant in univariate analysis. In conclusion, long-term survival can be achieved in patients with secondary CNS lymphoma. LDH at CNS manifestation and a CNS response to therapy were significantly associated with survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Alvarnas JC, Negrin RS, Horning SJ, Hu WW, Long GD, Schriber JR, Stockerl-Goldstein K, Tierney K, Wong R, Blume KG, Chao NJ (2000) High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin’s lymphoma. Biol Blood Marrow Transplant 6:352–358

    Article  PubMed  CAS  Google Scholar 

  2. Bashir RM, Bierman PJ, Vose JM, Weisenburger DD, Armitage JO (1991) Central nervous system involvement in patients with diffuse aggressive non-Hodgkin’s lymphoma. Am J Clin Oncol 14:478–482

    Article  PubMed  CAS  Google Scholar 

  3. Bertino JR (1986) Guidelines for reporting clinical trials. J Clin Oncol 4:1

    Google Scholar 

  4. Bokstein F, Lossos A, Lossos IS, Siegal T (2002) Central nervous system relapse of systemic non-Hodgkin’s lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy. Leuk Lymphoma 43:587–593

    Article  PubMed  CAS  Google Scholar 

  5. Bollen EL, Brouwer RE, Hamers S, Hermans J, Kluin M, Sankatsing SU, A-Tjak RV, Charvat MV, Kluin-Nelemans JC (1997) Central nervous system relapse in non-Hodgkin lymphoma. A single-center study of 532 patients. Arch Neurol 54:854–859

    PubMed  CAS  Google Scholar 

  6. Bos GM, van Putten WL, van der Holt B, van den Bent M, Verdonck LF, Hagenbeek A (1998) For which patients with aggressive non-Hodgkin’s lymphoma is prophylaxis for central nervous system disease mandatory? Dutch HOVON Group. Ann Oncol 9:191–194

    Article  PubMed  CAS  Google Scholar 

  7. Chamberlain MC, Kormanik PA (1996) Prognostic significance of 111indium-DTPA CSF flow studies in leptomeningeal metastases. Neurology 46:1674–1677

    PubMed  CAS  Google Scholar 

  8. Chamberlain MC, Kormanik PA (1997) Non-AIDS-related lymphomatous meningitis: combined modality therapy. Neurology 49:1728–1731

    PubMed  CAS  Google Scholar 

  9. Ersboll J, Schultz HB, Thomsen BL, Keiding N, Nissen NI (1985) Meningeal involvement in non-Hodgkin’s lymphoma: symptoms, incidence, risk factors and treatment. Scand J Haematol 35:487–496

    Article  PubMed  CAS  Google Scholar 

  10. Glantz MJ, Cole BF, Recht L, Akerley W, Mills P, Saris S, Hochberg F, Calabresi P, Egorin MJ (1998) High-dose intravenous methotrexate for patients with nonleukemic cancer: is intrathecal chemotherapy necessary? J Clin Oncol 16:1561–1567

    PubMed  CAS  Google Scholar 

  11. Hollender A, Kvaloy S, Lote K, Nome O, Holte H (2000) Prognostic factors in 140 adult patients with non-Hodgkin’s lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis. Eur J Cancer 36:1762–1768

    Article  PubMed  CAS  Google Scholar 

  12. Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H (2002) Central nervous system involvement following diagnosis of non-Hodgkin’s lymphoma: a risk model. Ann Oncol 13:1099–1107

    Article  PubMed  CAS  Google Scholar 

  13. Johnson GJ, Oken MM, Anderson JR, O’Connell MJ, Glick JH (1984) Central nervous system relapse in unfavourable-histology non-Hodgkin’s lymphoma: is prophylaxis indicated? Lancet 2(8404):685–687

    Article  PubMed  CAS  Google Scholar 

  14. Levitt LJ, Dawson DM, Rosenthal DS, Moloney WC (1980) CNS involvement in the non-Hodgkin’s lymphomas. Cancer 45:545–552

    Article  PubMed  CAS  Google Scholar 

  15. Litam JP, Cabanillas F, Smith TL, Bodey GP, Freireich EJ (1979) Central nervous system relapse in malignant lymphomas: risk factors and implications for prophylaxis. Blood 54:1249–1257

    PubMed  CAS  Google Scholar 

  16. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280

    PubMed  CAS  Google Scholar 

  17. MacKintosh FR, Colby TV, Podolsky WJ, Burke JS, Hoppe RT, Rosenfelt FP, Rosenberg SA, Kaplan HS (1982) Central nervous system involvement in non-Hodgkin’s lymphoma: an analysis of 105 cases. Cancer 49:586–595

    Article  PubMed  CAS  Google Scholar 

  18. Recht L, Straus DJ, Cirrincione C, Thaler HT, Posner JB (1988) Central nervous system metastases from non-Hodgkin’s lymphoma: treatment and prophylaxis. Am J Med 84:425–435

    Article  PubMed  CAS  Google Scholar 

  19. Siegal T, Sandbank U, Gabizon A, Siegal T, Mizrachi R, Ben-David E, Catane R (1987) Alteration of blood–brain–CSF barrier in experimental meningeal carcinomatosis. A morphologic and adriamycin-penetration study. J Neurooncol 4:233–242

    Article  PubMed  CAS  Google Scholar 

  20. Siegal T (1998) Leptomeningeal metastases: rationale for systemic chemotherapy or what is the role of intra-CSF-chemotherapy? J Neurooncol 38:151–157

    Article  PubMed  CAS  Google Scholar 

  21. van Besien K, Forman A, Champlin R (1997) Central nervous system relapse of lymphoid malignancies in adults: the role of high-dose chemotherapy. Ann Oncol 8:515–524

    Article  PubMed  Google Scholar 

  22. van Besien K, Ha CS, Murphy S, McLaughlin P, Rodriguez A, Amin K, Forman A, Romaguera J, Hagemeister F, Younes A, Bachier C, Sarris A, Sobocinski KS, Cox JD, Cabanillas F (1998) Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 91:1178–1184

    PubMed  Google Scholar 

  23. Williams CD, Pearce R, Taghipour G, Green ES, Philip T, Goldstone AH (1994) Autologous bone marrow transplantation for patients with non-Hodgkin’s lymphoma and CNS involvement: those transplanted with active CNS disease have a poor outcome—a report by the European Bone Marrow Transplant Lymphoma Registry. J Clin Oncol 12:2415–2422

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Oncology and Transfusion Medicine, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12200, Berlin, Germany

    Kristoph Jahnke, Eckhard Thiel, Stefan Schwartz & Agnieszka Korfel

  2. Department of Medical Informatics, Biometry and Epidemiology, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12200, Berlin, Germany

    Peter Martus

Authors
  1. Kristoph Jahnke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eckhard Thiel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Martus
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stefan Schwartz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Agnieszka Korfel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kristoph Jahnke.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jahnke, K., Thiel, E., Martus, P. et al. Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system. Ann Hematol 85, 45–50 (2006). https://doi.org/10.1007/s00277-005-1096-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-005-1096-3

Keywords

Search

Navigation